Multisystem Organ Failure of Sepsis: Multimedia

References

1. Harrois A, Huet O, Duranteau J. Alterations of mitochondrial function in sepsis and critical illness. Curr Opin Anaesthesiol. Apr 2009;22(2):143-9. [Medline].

2. Martin CM, Priestap F, Fisher H, Fowler RA, Heyland DK, Keenan SP, et al. A prospective, observational registry of patients with severe sepsis: the Canadian Sepsis Treatment and Response Registry. Crit Care Med. Jan 2009;37(1):81-8. [Medline].

3. Blanco J, Muriel-Bombín A, Sagredo V, Taboada F, Gandía F, Tamayo L, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care. 2008;12(6):R158. [Medline].

4. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med. Jan 2009;37(1):96-104. [Medline].

5. Nelson DP, Lemaster TH, Plost GN, Zahner ML. Recognizing sepsis in the adult patient. Am J Nurs. Mar 2009;109(3):40-5; quiz 46. [Medline].

6. [Best Evidence] Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, et al. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med. Apr 2009;37(4):1185-96. [Medline].

7. Adrie C, Alberti C, Chaix-Couturier C. Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as determinants of workload and cost. J Crit Care. Mar 2005;20(1):46-58.

8. Barriere SL, Lowry SF. An overview of mortality risk prediction in sepsis. Crit Care Med. Feb 1995;23(2):376-93. [Medline].

9. Bernard GR, Vincent JL, Laterre PF. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. Mar 8 2001;344(10):699-709. [Medline].

10. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med. Oct 15 1996;125(8):680-7. [Medline].

11. Bone RC. The pathogenesis of sepsis. Ann Intern Med. Sep 15 1991;115(6):457-69. [Medline].

12. Bone RC, Balk RA, Fein AM. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med. Jun 1995;23(6):994-1006. [Medline].

13. Bone RC, Fisher CJ Jr, Clemmer TP. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. Sep 10 1987;317(11):653-8. [Medline].

14. Bone RC, Fisher CJ Jr, Clemmer TP. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med. May 1989;17(5):389-93. [Medline].

15. Bracco D, Dubois MJ. Hemodynamic support in septic shock: is restoring a normal blood pressure the right target?. Crit Care Med. Sep 2005;33(9):2113-5.

16. Brun-Buisson C, Doyon F, Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med. Sep 1996;154(3 Pt 1):617-24. [Medline].

17. Choi PT, Yip G, Quinonez LG. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med. Jan 1999;27(1):200-10. [Medline].

18. Dragsted L, Jorgensen J, Jensen NH. Interhospital comparisons of patient outcome from intensive care: importance of lead-time bias. Crit Care Med. May 1989;17(5):418-22. [Medline].

19. Gando S, Iba T, Eguchi Y. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. Mar 2006;34(3):625-31. [Medline].

20. Higgins TL, Steingrub JS, Tereso GJ. Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes. J Intensive Care Med. Nov-Dec 2005;20(6):339-45.

21. Knaus WA, Draper EA, Wagner DP. APACHE II: a severity of disease classification system. Crit Care Med. Oct 1985;13(10):818-29. [Medline].

22. Knaus WA, Sun X, Nystrom O. Evaluation of definitions for sepsis. Chest. Jun 1992;101(6):1656-62. [Medline].

23. Knaus WA, Wagner DP, Draper EA. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. Dec 1991;100(6):1619-36. [Medline].

24. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. Mar 1980;68(3):344-55. [Medline].

25. Krejci V, Hiltebrand LB, Sigurdsson GH. Effects of epinephrine, norepinephrine, and phenylephrine on microcirculatory blood flow in the gastrointestinal tract in sepsis. Crit Care Med. May 2006;34(5):1456-63.

26. Luce JM. Pathogenesis and management of septic shock. Chest. Jun 1987;91(6):883-8. [Medline].

27. Marsh R, Nadel ES, Brown DF. Multisystem organ failure. J Emerg Med. Oct 2005;29(3):331-4.

28. Marshall JC, Cook DJ, Christou NV. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. Oct 1995;23(10):1638-52. [Medline].

29. Nguyen HB, Corbett SW, Menes K. Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department. Acad Emerg Med. Jan 2006;13(1):109-13.

30. Pinsky MR, Matuschak GM. Multiple systems organ failure: failure of host defense homeostasis. Crit Care Clin. Apr 1989;5(2):199-220. [Medline].

31. Rangel-Frausto MS. Sepsis: still going strong. Arch Med Res. Nov-Dec 2005;36(6):672-81.

32. Revelly JP, Tappy L, Martinez A. Lactate and glucose metabolism in severe sepsis and cardiogenic shock. Crit Care Med. Oct 2005;33(10):2235-40.

33. Rivers EP. Early goal-directed therapy in severe sepsis and septic shock: converting science to reality. Chest. Feb 2006;129(2):217-8.

34. Sands KE, Bates DW, Lanken PN. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA. Jul 16 1997;278(3):234-40. [Medline].

35. Sasse KC, Nauenberg E, Long A. Long-term survival after intensive care unit admission with sepsis. Crit Care Med. Jun 1995;23(6):1040-7. [Medline].

36. Shubin H, Weil MH. Bacterial shock. JAMA. Jan 26 1976;235(4):421-4. [Medline].

37. Sutherland AM, Gordon AC, Russell JA. Are vasopressin levels increased or decreased in septic shock?. Crit Care Med. Feb 2006;34(2):542-3.

38. Tsai MH, Peng YS, Chen YC. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. Apr 2006;43(4):673-81.

39. Vincent JL, Bihari DJ, Suter PM. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. Aug 23-30 1995;274(8):639-44. [Medline].

40. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. Jan 21 1999;340(3):207-14. [Medline].

41. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med. Jul 1997;25(7):1095-100. [Medline].

Further Reading

Clinical guidelines

Drotrecogin alfa (activated) for severe sepsis.
National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.].  2004 Sep.  31 pages.  NGC:004523

Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update.
Society of Critical Care Medicine - Professional Association.  2004 Sep.  21 pages.  NGC:004181

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Society of Critical Care Medicine - Professional Association.  2004 (revised 2008 Jan).  44 pages.  NGC:006316

Clinical trials

Regulation of Endocrine, Metabolic, Immune and Bioenergetic Responses in Sepsis

Uremic Toxins in the Intensive Care Unit (ICU): Patients With Sepsis

Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis


Related eMedicine topics

Acute Renal Failure

Acute Respiratory Distress Syndrome

Cardiogenic Shock

Sepsis, Bacterial

Septic Shock

Keywords

multisystem organ failure of sepsis, sepsis, organ failure, multiple organ failure, organ failures, multiple system organ failure, multiple organ system failure, multiple organ dysfunction syndrome, MODS

Contributor Information and Disclosures

Coauthor(s)

Sat Sharma, MD, FRCPC, Professor and Head, Division of Pulmonary Medicine, Department of Internal Medicine, University of Manitoba; Site Director, Respiratory Medicine, St. Boniface General Hospital
Sat Sharma, MD, FRCPC is a member of the following medical societies: American Academy of Sleep Medicine, American College of Chest Physicians, American College of Physicians-American Society of Internal Medicine, American Thoracic Society, Canadian Medical Association, Royal College of Physicians and Surgeons of Canada, Royal Society of Medicine, Society of Critical Care Medicine, and World Medical Association
Disclosure: Nothing to disclose.

Gregg Eschun, MD, Assistant Professor, Department of Internal Medicine, Sections of Respirology and Critical Care, St Boniface Hospital, University of Manitoba, Canada
Gregg Eschun, MD is a member of the following medical societies: American College of Chest Physicians, American Thoracic Society, Canadian Medical Association, and College of Physicians and Surgeons of Manitoba
Disclosure: Nothing to disclose.

Medical Editor

Cory Franklin, MD, Professor, Department of Medicine, Rosalind Franklin University of Medicine and Science; Director, Division of Critical Care Medicine, Cook County Hospital
Cory Franklin, MD is a member of the following medical societies: New York Academy of Sciences and Society of Critical Care Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Daniel R Ouellette, MD, FCCP, Associate Professor of Medicine, Wayne State University School of Medicine; Consulting Staff, Pulmonary Disease and Critical Care Medicine Service, Henry Ford Health System
Daniel R Ouellette, MD, FCCP is a member of the following medical societies: American College of Chest Physicians and American Thoracic Society
Disclosure: Boehringer Ingleheim Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching

CME Editor

Timothy D Rice, MD, Associate Professor, Departments of Internal Medicine and Pediatrics and Adolescent Medicine, Saint Louis University School of Medicine
Timothy D Rice, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Physicians
Disclosure: Nothing to disclose.

Chief Editor

Michael R Pinsky, MD, CM, FCCP, FCCM, Professor of Critical Care Medicine, Bioengineering, Cardiovascular Disease and Anesthesiology, Vice-Chair, Academic Affairs, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center
Michael R Pinsky, MD, CM, FCCP, FCCM is a member of the following medical societies: American College of Chest Physicians, American College of Critical Care Medicine, American Heart Association, American Thoracic Society, Association of University Anesthetists, Shock Society, and Society of Critical Care Medicine
Disclosure: LiDCO Ltd Honoraria Consulting; iNTELOMED Intellectual property rights Board membership; Edwards Lifesciences Honoraria Consulting; Applied Physiology, Ltd Honoraria Consulting; Cheetah Medical Consulting fee Consulting